Business
Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET
Webcast to be held Wednesday, August 9, 4:30 p.m. ET, register here, or at the link below. DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), an
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nWebcast to be held Wednesday, August 9, 4:30 p.m. ET, register here, or at the link below.\n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its second quarter 2023 operating and financial results webcast on Wednesday, August 9, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.\n\n\nManagement intends to discuss the operating and financial results for the second quarter ended June 30, 2023 and provide guidance on upcoming milestones. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team.\n\n\nTo register for the webcast, sign up at the link below:\nhttps://us06web.zoom.us/webinar/register/1016902973506/WN_h4QZ0ZyxR3mZZbNQxa2eMw\n\n\nA replay of the webcast will be available after the call on the investor relations section of the Company's website at ir.lanternpharma.com.\n\n\nAbout Lantern Pharma:\n\n\nLantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.\n\n\nOur lead development programs include two Phase 2 clinical programs and multiple upcoming Phase 1 clinical trials anticipated for 2023. We have also established a wholly-owned subsidiary, Starlight Therapeutics Inc., to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. ...